A Randomized, Double-blind, Placebo-controlled Phase 2b Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 24 Mar 2025
At a glance
- Drugs ZSP-1601 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Guangdong Raynovent Biotech
Most Recent Events
- 19 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Status changed from not yet recruiting to recruiting.
- 23 Jan 2023 New trial record